Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.1 NOK | +2.45% | -14.56% | -94.22% |
04-17 | Ultimovacs to Reduce 40% of Workforce Amid Operational Adjustments | MT |
04-17 | Transcript : Ultimovacs ASA - Special Call |
Sales 2024 * | 954M 86.49M 6.92B | Sales 2025 * | - | Capitalization | 244M 22.16M 1.77B |
---|---|---|---|---|---|
Net income 2024 * | 654M 59.32M 4.74B | Net income 2025 * | -140M -12.7M -1.02B | EV / Sales 2024 * | -0.98 x |
Net cash position 2024 * | 1.18B 107M 8.54B | Net cash position 2025 * | 1.05B 95.19M 7.61B | EV / Sales 2025 * | - |
P/E ratio 2024 * |
0.43
x | P/E ratio 2025 * |
-1.86
x | Employees | 26 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.97% |
Latest transcript on Ultimovacs ASA
1 day | +2.45% | ||
1 week | -14.56% | ||
Current month | -10.92% | ||
1 month | -7.67% | ||
3 months | -94.86% | ||
6 months | -92.85% | ||
Current year | -94.22% |
Managers | Title | Age | Since |
---|---|---|---|
Carlos de Sousa
CEO | Chief Executive Officer | 66 | 31/05/20 |
Director of Finance/CFO | 57 | - | |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jónas Einarsson
CHM | Chairman | 67 | 25/01/11 |
Henrik Schüssler
BRD | Director/Board Member | 61 | 31/12/14 |
Kari Grønås
BRD | Director/Board Member | 59 | 31/12/18 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 7.1 | +2.45% | 348,026 |
25/04/24 | 6.93 | -8.58% | 840,001 |
24/04/24 | 7.58 | -3.56% | 496,380 |
23/04/24 | 7.86 | -0.51% | 287,821 |
22/04/24 | 7.9 | -4.93% | 261,462 |
Real-time Oslo Bors, April 26, 2024 at 03:45 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-94.22% | 22.12M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ULTI Stock